Lymphotactin enhances the in-vitro immune efficacy of dendritoma formed by dendritic cells and mouse hepatocellular carcinoma cells

J Zhejiang Univ Sci. 2004 Oct;5(10):1255-61. doi: 10.1631/jzus.2004.1255.

Abstract

Objective: To investigate the in-vitro antitumor immune responses of dendritoma formed by mouse hepatocellular carcinoma (HCC) cells and lymphotactin (Lptn) gene modified dendritic cells (DCs).

Method: DCs prepared from mouse bone marrow were genetically modified by lymphotactin adenovirus, and fused with H22 cells by polyethylene glycol (PEG). RT-PCR and ELISA were employed to identify lymphotactin expression at mRNA and protein level. Cell phenotypes and fusion efficiency was detected by FACS. The stimulatory effect of DC on T cells was detected by mixed lymphocyte reaction. The cytotoxicity activity against H22 cells was assayed by LDH method.

Results: Lymphotactin could be efficiently expressed by DCLptn/H22 hybridoma. DCLptn/H22 cells could induce potent T cell proliferation effect and generate strong cytotoxic T lymphocyte (CTL) reaction against allogenic H22 cells.

Conclusion: Lymphotactin genetic modification could enhance the in vitro immune activity of the dendritoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Carcinoma, Hepatocellular / immunology*
  • Cell Fusion / methods*
  • Cells, Cultured
  • Chemokines, C / genetics
  • Chemokines, C / immunology*
  • Dendritic Cells / immunology*
  • Female
  • Immunization / methods*
  • Lymphocyte Activation / immunology*
  • Mice
  • Mice, Inbred BALB C
  • Recombinant Proteins / immunology
  • T-Lymphocytes / immunology*

Substances

  • Chemokines, C
  • Recombinant Proteins
  • Xcl1 protein, mouse